Madrid, Spain, April 7th, 2010. Felipe Ptriz, Secretary of State for Research and Emilio Botn, President of the Grupo Santander, signed today a milestone agreement giving birth to the PESA (Progression of Early Subclinical Atherosclerosis) CNIC-Santander trial. The project's main goal is to increase the knowledge about cardiovascular diseases. The investigation, headed by Valentn Fuster, MD, PhD, Chairman of the Centro Nacional de Investigaciones Cardiovasculares* (CNIC) and Heart Director at the Mount Sinai in New York, will help improve current prevention strategies regarding atherosclerotic pathologies major cause of death worldwide-; additionally, this initiative will aim to identify risk factors and daily habits that certainly have an influence on these disorders' development. The final objective would consist on achieving an early diagnose before symptoms appear.
The Medical Services of Banco Santander and of the CNIC (this one under the control of the Ministry of Science and Innovation) will work together in this trial. So far, authors expect to enroll over 3.000 employees from Banco Santander, who will all have access to the best and more advanced imaging and lab technology, in which utility and accuracy are the main goal for the scientific community.
The PESA CNIC-Santander trial takes part in a series of relevant international investigations designed to improve diagnose and prophylaxis of cardiovascular diseases. In fact, this project is connected to a US-based trial assessing people of over 60 years old.
In this case, investigators expect to determine the association between cardiovascular risk factors, both emerging and traditional ones, and the evolution of the disease before symptoms show up. This is the reason behind the sample of population studied by PESA trial being based on healthy people between 40 and 54 years of age, a life period usually out free of this kind of disorders.
The PESA CNIC-Santand
|Contact: Pilar Berengena|
Spanish National Cardiovascular Research Center (CNIC)